c-semaglutide Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients Semaglutide | C187H291N45O59 | CID

Because of its acute hypoglycemic function, semaglutide was first marketed as an anti-diabetic medication

Short study duration (7 hours) and controlled setting may not reflect real-world conditions

As Dr Sullivan commented, the benefit appears to increase over time rather than fade, and that it behaves like a drug in terms of dose response. Dr Sullivan and colleagues concluded that these results support DMR as a promising, procedure-based strategy to maintain weight loss and potentially enable shorter-duration GLP-1 therapy. In a press release, Dr Sullivan noted, Finding a treatment that allows patients to stop [GLP-1] medications without weight regain or loss of metabolic benefit is a huge unmet need. She continued, These findings indicate that this minimally invasive procedure may provide lasting weight-loss maintenance. Six-month cohort data from the REMAIN-1 trial are expected to be reported late in 2026.

PepsiCo is pivotally shifting 70% of its food business toward single-serve, functional snacks (high-fiber/protein) as users skip high-volume bags in favor of mini-meal rituals

Ordered Monday, reviewed Tuesday and arrived on Wednesday